These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6158677)

  • 21. Local and long-range structural effects caused by the removal of the N-terminal polypeptide fragment from immunoglobulin L chain lambda.
    Król M; Roterman I; Piekarska B; Konieczny L; Rybarska J; Stopa B
    Biopolymers; 2003 Jun; 69(2):189-200. PubMed ID: 12767122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display.
    Hughes DL; Stafford P; Hamaia SW; Harmer lJ; Schoolmeester A; Deckmyn H; Farndale RW; Ouwehand WH; Watkins NA
    Thromb Haemost; 2005 Dec; 94(6):1318-26. PubMed ID: 16411412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Origins of antibody complementarity and specificity--hypervariable regions and minigene hypothesis.
    Kabat EA
    J Immunol; 1980 Sep; 125(3):961-9. PubMed ID: 6774021
    [No Abstract]   [Full Text] [Related]  

  • 24. Combining site and antigenic determinants of the V regions.
    Givol D; Gavish M; Zakut R; Ben-Neriah Y; Lonai P
    Haematologia (Budap); 1978-1979; 12(1-4):15-24. PubMed ID: 94027
    [No Abstract]   [Full Text] [Related]  

  • 25. DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain.
    Chen Y; Stollar BD
    J Immunol; 1999 Apr; 162(8):4663-70. PubMed ID: 10202006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arrangement of lambda light chain genes in mutant clones of the MOPC 315 mouse myeloma cells.
    Hozumi N; Wu G; Murialdo H; Baumal R; Mosmann T; Winberry L; Marks A
    J Immunol; 1982 Jul; 129(1):260-6. PubMed ID: 6806362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel antibody AA98 V(H)/L directed against CD146 efficiently inhibits angiogenesis.
    Lin Y; Wu X; Shen Y; Bu P; Yang D; Yan X
    Anticancer Res; 2007; 27(6B):4219-24. PubMed ID: 18225593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational flexibility of an antibody combining site composed of two identical V regions.
    Gavish M; Dwek RA; Givol D
    Eur J Immunol; 1978 Jan; 8(1):42-6. PubMed ID: 25187
    [No Abstract]   [Full Text] [Related]  

  • 30. Domain interactions and antigen binding of recombinant anti-Z-DNA antibody variable domains. The role of heavy and light chains measured by surface plasmon resonance.
    Polymenis M; Stollar BD
    J Immunol; 1995 Mar; 154(5):2198-208. PubMed ID: 7868893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constant heavy-chain (CH1) and L-chain dependence of rabbit VH allotype determinants demonstrated by polyethylene glycol precipitation radioimmunoassays.
    Jensenius JC; Johnstone AP; Crone M; Andersen I
    Mol Immunol; 1982 Apr; 19(4):571-7. PubMed ID: 6178015
    [No Abstract]   [Full Text] [Related]  

  • 32. The variable region of human immunoglobulins. I. Serologic and structural correlations of antigenic markers common to V lambda I and V lambda IV proteins (isotypic cross-reactivities).
    Rivat-Peran L; Tischendorf FW; Dumitresco SM; Rivat C; Tischendorf MM; Haas H; Deutsch HF
    J Immunol; 1980 Jul; 125(1):270-7. PubMed ID: 6155400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The structural basis of antigenic determinants on V kappa 21 light chains.
    Julius MA; McKean DJ; Potter M; Feldmann RJ; Weigert M
    Mol Immunol; 1981 Jan; 18(1):1-9. PubMed ID: 6167848
    [No Abstract]   [Full Text] [Related]  

  • 34. A small hypervariable segment in the variable domain of an immunoglobulin light chain stimulates formation of anti-idiotypic suppressor T cells.
    Sakato N; Semma M; Eisen HN; Azuma T
    Proc Natl Acad Sci U S A; 1982 Sep; 79(17):5396-400. PubMed ID: 6215651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulins with hapten-binding activity: structure-function correlations and genetic implications.
    Barstad P; Hubert J; Hunkapiller M; Goetze A; Schilling J; Black B; Eaton B; Richards J; Weigert M; Hood L
    Eur J Immunol; 1978 Jul; 8(7):497-503. PubMed ID: 689076
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of a third type of lambda light chain in mouse immunoglobulins.
    Azuma T; Steiner LA; Eisen HN
    Proc Natl Acad Sci U S A; 1981 Jan; 78(1):569-73. PubMed ID: 6165998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helper T cell recognition of the variable domains of a mouse myeloma protein (315). Effect of the major histocompatibility complex and domain conformation.
    Jørgensen T; Hannestad K
    J Exp Med; 1982 Jun; 155(6):1587-96. PubMed ID: 6978921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Isolation and characterization of the matrix properties of electrophoretically homogeneous immunoglobulin L-chain mRNA from mouse myeloma MORC 21].
    Barbakar' NI; Sakharova NK; Goriunova LE; Grechko VV
    Mol Biol (Mosk); 1980; 14(2):402-12. PubMed ID: 6155605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of kappa chains of the V kappa 21 group in Mus musculus and related species.
    Julius MA; McKean DJ; Potter M; Weigert M
    Mol Immunol; 1981 Jan; 18(1):11-7. PubMed ID: 6167849
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of isotype exclusion and expression of aberrant lambda light chain on secreted MOPC-315 myeloma proteins.
    Ju ST; Pinto D; Dorf ME
    Mol Immunol; 1986 Jan; 23(1):79-85. PubMed ID: 3083241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.